Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients
- 21 August 2013
- journal article
- clinical trial
- Published by Taylor & Francis Ltd in Acta Oncologica
- Vol. 53 (3), 399-404
- https://doi.org/10.3109/0284186x.2013.820342
Abstract
Since 2005, we have treated hepatocellular carcinoma (HCC) with stereotactic body radiotherapy (SBRT) uniformly at two dose levels, according to baseline liver function and normal liver dose. We retrospectively examined the outcomes for these patients. Between 2005 and 2012, 221 HCC patients were treated with SBRT. Eligibility criteria for SBRT included a single (either solitary or recurrent) HCC lesion; unfeasible, difficult or refusal to undergo other surgery or percutaneous ablative therapies; Child-Pugh Classification (CPC) A or B; tumors ≤ 5 cm; dose to the bowels < 25 Gy/5 fractions; curative intent. Patients followed up ≥ 6 months were eligible. The prescribed dose depended on liver function and liver dose: 40 Gy for CPC-A and 35 Gy for CPC-B, in 5 fractions, requiring a 5-Gy dose reduction if the proportion of the liver receiving ≥ 20 Gy exceeded 20%. Treatment outcomes and safety were analyzed. A total of 185 patients (n = 48 in the 35-Gy group; n = 137 in the 40-Gy group) were eligible, with a median follow-up duration of 24 months (range 3-80). The three-year local control and overall survival rates were 91% and 70%, respectively. There were no significant differences in outcomes between dose levels: the three-year local control and overall survival rates in the 35-Gy and 40-Gy groups were 91% and 89% (log-rank p = 0.99) and 66% and 72% (p = 0.54), respectively. Acute toxicities ≥ grade 3 were observed in 24 (13.0%) patients, and 19 (10.3%) patients had worsening of CPC score by two points. All but three (1.6%) patients promptly recovered to grade 1-2. Grade 5 liver failure occurred in two patients in the 35-Gy group. SBRT for HCC was safe and provided equivalent outcomes when administered either in 35 or 40 Gy/5 fractions.Keywords
This publication has 21 references indexed in Scilit:
- Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2012
- Stereotactic Body Radiation Therapy in Recurrent Hepatocellular CarcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolizationCancer, 2012
- Stereotactic Body Radiotherapy for Primary Hepatocellular CarcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Stereotactic Radiotherapy of Hepatocellular Carcinoma: Preliminary ResultsTechnology in Cancer Research & Treatment, 2010
- Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinomaClinical and Translational Oncology, 2010
- Stereotactic body radiation therapy for liver metastasesEuropean Journal of Cancer, 2009
- Diagnosis and Treatment of Hepatocellular CarcinomaGastroenterology, 2008
- Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaJournal of Clinical Oncology, 2008
- Ultraselective Transcatheter Arterial Chemoembolization with a 2-F Tip Microcatheter for Small Hepatocellular Carcinomas: Relationship Between Local Tumor Recurrence and Visualization of the Portal Vein with Iodized OilJournal of Vascular and Interventional Radiology, 2007